TFTom T. Fischer

Tom T. Fischer

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tom T. Fischer has a total of 105 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A single-cell atlas of cancer-educated ecotypes across high-risk pediatric sarcomas

    by Christian Seitz, Karla Catacora Castañeda, Sophia Scheuermann, Tom Fischer, Fabienne Engelmann, Anke King, Roland Imle, Alice Nuernbergk, Beate Kristmann, Jan-Philipp Mallm, et al.

    High-risk pediatric sarcomas have a dismal prognosis. Current precision oncology approaches have not substantially improved patient outcomes. Immunotherapy offers a unique opportunity to develop more effective treatment strategies, but its successful implementation is hindered by a limited understanding of the tumor microenvironment (TME). We generated a TME classification platform by performing single-nucleus RNA sequencing of 89 pediatric sarcoma samples representing the major entities and integrating these data with high-dimensional spatial imaging. We identified distinct stromal, myeloid, and lymphoid cell states, revealing both entity-specific and conserved functional programs. Compositional analyses demonstrated marked differences in immune and stromal infiltration, with inflammatory myeloid cells dominating most tumors. We defined twelve TME archetypes and identified convergent multicellular niches, including stroma-, vasculature-, and T cell-rich regions, validated by multiplex imaging. Cell-cell interaction analyses uncovered shared and entity-specific communication networks, providing a comprehensive atlas of pediatric sarcoma TMEs and a framework for rational immunotherapeutic development.


  • Top Cited Papers
    Open Access

    M-PACT leverages cell-free DNA methylomes to achieve robust classification of pediatric brain tumors

    by Kyle S. Smith, Tom T. Fischer, Katie Han, Anna Kostecka, Hong Lin, Daniel Senfter, Taha Soliman, Natalia Stepien, Stefanie Volz, Nathalie Schwarz, et al.

    Cerebrospinal fluid (CSF) liquid biopsies serve as a rich source of tumor-derived cell-free DNA (cfDNA) for evaluating persons with central nervous system (CNS) tumors. However, challenges stemming from trace cfDNA yields and low mutational burden have hindered sensitivity, whereas first-generation clinical assays have relied on genetic alterations as biomarkers. Leveraging the diagnostic utility of DNA methylation classification in CNS tumors, we developed M-PACT (methylation-based predictive algorithm for CNS tumors), a robust deep neural network that accurately classifies tumors from subnanogram-input cfDNA methylomes. Across embryonal CNS tumor benchmarking (n = 79) and validation (n = 58) cohorts, M-PACT achieved 92% and 88% accuracy, respectively. We further showcase M-PACT utility in nonembryonal CNS tumors, balanced tumor genomes and nonmalignant CSF. Beyond classification, this workflow enables methylation-based cellular deconvolution and sensitive copy-number variation detection. Altogether, we provide a blueprint for CNS tumor classification from low-input cfDNA methylomes, motivating prospective validation for future clinical implementation.


  • Open Access

    Ultra-low-input cell-free DNA sequencing for tumor detection and characterization in a real-world pediatric brain tumor cohort

    by Tom T. Fischer, Kendra K. Maaß, Pitithat Puranachot, Markus Mieskolainen, Martin Sill, Paulina S. Schad, Stefanie Volz, Fabian Rosing, Tatjana Wedig, Nathalie Schwarz, et al.

    Molecular profiling of pediatric central nervous system (CNS) tumors has important clinical utility for guiding diagnostic and therapeutic strategies. Cell-free DNA (cfDNA) from liquid biopsies has been used for minimally invasive tumor profiling and longitudinal disease assessment in adult oncology and pediatric hematology. However, in pediatric neuro-oncology, low cfDNA yields pose a major barrier to translating these assays from bench to bedside. Here, we implemented a low-coverage whole genome sequencing (lcWGS) assay for picogram-level cfDNA inputs and applied it to liquid biopsies from a sizeable, population-based, cross-entity pediatric CNS tumor cohort (n = 56 patients). Applying this protocol, cfDNA whole genome profiles were successfully acquired from all liquid biopsy samples (n = 61/61 serum, n = 56/56 CSF, 100%). Based on copy number variations (CNVs), circulating-tumor DNA (ctDNA) was detected in 2/61 serum (3%) and in 25/56 CSF (45%) samples across various brain tumor entities. The integration of cfDNA results with clinical data demonstrated the utility of CSF lcWGS as a biomarker assay at diagnosis to distinguish cancerous from non-cancerous pineal region lesions (n = 6 patients). Additionally, serial CSF assessment in n = 9 patients (n = 29 CSF samples) enabled minimally invasive disease monitoring, with the added value of molecular profile availability in n = 4/6 (67%) patients at relapse. Proof-of-concept data show the feasibility of serial CSF lcWGS to reveal tumor evolution, tumor heterogeneity and potential therapeutic vulnerabilities in a case of medulloblastoma and germ cell tumor. Our study underscores the clinical utility of a robust lcWGS-based liquid biopsy assay optimized for low-input samples. We identify use-cases for implementing liquid biopsies in the clinical management of pediatric CNS tumor patients and provide a strong rationale for integration into future trials.


  • Open Access

    CSF liquid biopsy guides differential diagnosis of relapsed medulloblastoma versus secondary glioma: case report of a pediatric patient enrolled on a PDGFRA inhibitor trial

    by Tom T Fischer, Kendra K Maass, Melanie Schoof, Pitithat Puranachot, Philipp Sievers, Sophia Montigel, Theresa Fluhr, Ahmed El Damaty, Angelika Seitz, Semi Harrabi, et al.

    Liquid biopsies have the potential to substantially transform clinical oncology, but their technical applicability and clinical utility in pediatric neuro-oncology remain to be explored. Here, we present a case of a medulloblastoma patient in which a cerebrospinal fluid liquid biopsy provided an accurate molecular tumor classification of a secondary glioma during follow-up. Using nanopore sequencing and low-coverage whole genome sequencing pipelines optimized for cell-free DNA, the liquid biopsy revealed a PDGFRA amplification and DNA methylation-based tumor classification consistent with a secondary glioma. These findings guided the tumor board’s differential diagnosis of medulloblastoma relapse versus secondary glioma. Notably, the rapid turnaround time of the nanopore sequencing results enabled timely preparation for enrollment in a PDGFRA inhibitor trial while awaiting confirmatory results from the tissue biopsy. This case exemplifies the advancing frontier of liquid biopsies and provides the rationale for prospective implementation in larger case series and clinical trials in pediatric neuro-oncology.


  • Boosting ER-mitochondria calcium transfer to treat Wolfram syndrome

    by Tom T. Fischer, Lien D. Nguyen, Barbara E. Ehrlich


  • Open Access

    Cytoskeletal dynamics regulates stromal invasion behavior of distinct liver cancer subtypes

    by Ryan Y. Nguyen, Hugh Xiao, Xiangyu Gong, Alfredo Arroyo, Aidan T. Cabral, Tom T. Fischer, Kaitlin M. Flores, Xuchen Zhang, Marie E. Robert, Barbara E. Ehrlich, et al.

    Drug treatment against liver cancer has limited efficacy due to heterogeneous response among liver cancer subtypes. In addition, the functional biophysical phenotypes which arise from this heterogeneity and contribute to aggressive invasive behavior remain poorly understood. This study interrogated how heterogeneity in liver cancer subtypes contributes to differences in invasive phenotypes and drug response. Utilizing histological analysis, quantitative 2D invasion metrics, reconstituted 3D hydrogels, and bioinformatics, our study linked cytoskeletal dynamics to differential invasion profiles and drug resistance in liver cancer subtypes. We investigated cytoskeletal regulation in 2D and 3D culture environments using two liver cancer cell lines, SNU-475 and HepG2, chosen for their distinct cytoskeletal features and invasion profiles. For SNU-475 cells, a model for aggressive liver cancer, many cytoskeletal inhibitors abrogated 2D migration but only some suppressed 3D migration. For HepG2 cells, cytoskeletal inhibition did not significantly affect 3D migration but did affect proliferative capabilities and spheroid core growth. This study highlights cytoskeleton driven phenotypic variation, their consequences and coexistence within the same tumor, as well as efficacy of targeting biophysical phenotypes that may be masked in traditional screens against tumor growth.


  • Neuronal calcium sensor 1 (NCS1) dependent modulation of neuronal morphology and development

    by Tom T. Fischer, Lien D. Nguyen, Barbara E. Ehrlich

    Calcium (Ca 2+ ) signaling is critical for neuronal functioning and requires the concerted interplay of numerous Ca 2+ ‐binding proteins, including neuronal calcium sensor 1 (NCS1). Although an important role of NCS1 in neuronal processes and in neurodevelopmental and neurodegenerative diseases has been established, the underlying mechanisms remain enigmatic. Here, we systematically investigated the functions of NCS1 in the brain. Using Golgi‐Cox staining, we observed a reduction in dendritic complexity and spine density in the prefrontal cortex and the dorsal hippocampus of Ncs1 −/− mice, which may underlie concomitantly observed deficits in memory acquisition. Subsequent RNA sequencing of Ncs1 −/− and Ncs1 +/+ mouse brain tissues revealed that NCS1 modulates gene expression related to neuronal morphology and development. Investigation of developmental databases further supported a molecular role of NCS1 during brain development by identifying temporal gene expression patterns. Collectively, this study provides insights into NCS1‐dependent signaling and lays the foundation for a better understanding of NCS1‐associated diseases.


  • Open Access

    Pharmacological rescue of cognitive function in a mouse model of chemobrain

    by Lien D. Nguyen, Tom T. Fischer, Barbara E. Ehrlich

    Background: After chemotherapy, many cancer survivors suffer from long-lasting cognitive impairment, colloquially known as “chemobrain.” However, the trajectories of cognitive changes and the underlying mechanisms remain unclear. We previously established paclitaxel-induced inositol trisphosphate receptor (InsP3R)-dependent calcium oscillations as a mechanism for peripheral neuropathy, which was prevented by lithium pretreatment. Here, we investigated if a similar mechanism also underlay paclitaxel-induced chemobrain. Method: Mice were injected with 4 doses of 20 mg/kg paclitaxel every other day to induced cognitive impairment. Memory acquisition was assessed with the displaced object recognition test. The morphology of neurons in the prefrontal cortex and the hippocampus was analyzed using Golgi-Cox staining, followed by Sholl analyses. Changes in protein expression were measured by Western blot. Results: Mice receiving paclitaxel showed impaired short-term spatial memory acquisition both acutely 5 days post injection and chronically 23 days post injection. Dendritic length and complexity were reduced in the hippocampus and the prefrontal cortex after paclitaxel injection. Concurrently, the expression of protein kinase C α (PKCα), an effector in the InsP3R pathway, was increased. Treatment with lithium before or shortly after paclitaxel injection rescued the behavioral, cellular, and molecular deficits observed. Similarly, memory and morphological deficits could be rescued by pretreatment with chelerythrine, a PKC inhibitor. Conclusion: We establish the InsP3R calcium pathway and impaired neuronal morphology as mechanisms for paclitaxel-induced cognitive impairment. Our findings suggest lithium and PKC inhibitors as candidate agents for preventing chemotherapy-induced cognitive impairment.


  • Calpain inhibitor and ibudilast rescue β cell functions in a cellular model of Wolfram syndrome

    by Lien D. Nguyen, Tom T. Fischer, Damien Abreu, Alfredo Arroyo, Fumihiko Urano, Barbara E. Ehrlich

    Significance: Wolfram syndrome is a rare multisystem disease characterized by diabetes insipidus, diabetes mellitus, optic nerve atrophy, and deafness (DIDMOAD). It is primarily caused by mutations in the Wolfram syndrome 1 gene, WFS1 . As a monogenetic disorder, Wolfram syndrome is a model for diabetes and neurodegeneration. There is no effective treatment for this invariably fatal disease. Here we characterize WFS1 as a regulator of calcium homeostasis and subsequently target calcium signaling to reverse deficits in a cellular model of Wolfram syndrome.